Barinthus Biotherapeutics (BRNS) Current Leases (2020 - 2026)

Barinthus Biotherapeutics has reported Current Leases for 7 years, with the latest figure at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 2.3% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (up 2.3% YoY), and the FY2025 full-year result was $2.0 million, up 5.36% from the prior year.
• Current Leases for Q1 2026 stood at $2.0 million, down from $2.0 million in the prior quarter.
• The five-year high for Current Leases was $2.0 million in Q2 2025, with the low at $186000.0 in Q3 2022.
• Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.9 million in 2024.
• Annual changes were most pronounced in 2022 — Current Leases slumped 57.24% — and 2023, when it soared 706.99%.
• Barinthus Biotherapeutics' Current Leases stood at $433000.0 in 2022, then surged by 312.24% to $1.8 million in 2023, then climbed by 7.56% to $1.9 million in 2024, then gained by 5.36% to $2.0 million in 2025, then declined by 0.89% to $2.0 million in 2026.
• The last three Current Leases figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.